• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用期中分析确定样本量。

Sample size determination using an interim analysis.

作者信息

Bristol D R

机构信息

Schering-Plough Research Institute, Kenilworth, New Jersey 07033.

出版信息

J Biopharm Stat. 1993 Sep;3(2):159-66. doi: 10.1080/10543409308835057.

DOI:10.1080/10543409308835057
PMID:8220401
Abstract

Interim analyses are often employed to terminate comparative clinical trials for ethical or economic reasons when the evidence indicates that one treatment is superior to the other. Here an interim analysis is proposed for the situation where a one-sided test is to be performed. The proposed interim analysis consists of a one-sided test to terminate the clinical trial if it appears that the null hypothesis of interest is true. By noting that incorporation of a single interim analysis is similar to the two-stage procedure used for constructing a test procedure with power independent of the unknown variance, it also includes estimation of the variance, which can be used to control the power of the test if the trial is not terminated. Various properties of this two-stage procedure and derivation of the constants needed for its implementation are presented.

摘要

出于伦理或经济原因,当证据表明一种治疗方法优于另一种治疗方法时,中期分析通常用于终止比较性临床试验。本文针对单侧检验的情况提出了一种中期分析方法。所提出的中期分析包括一个单侧检验,如果感兴趣的原假设似乎为真,则终止临床试验。通过注意到纳入单一中期分析类似于用于构建功效与未知方差无关的检验程序的两阶段程序,它还包括方差估计,如果试验未终止,该估计可用于控制检验的功效。本文给出了该两阶段程序的各种性质及其实施所需常数的推导。

相似文献

1
Sample size determination using an interim analysis.使用期中分析确定样本量。
J Biopharm Stat. 1993 Sep;3(2):159-66. doi: 10.1080/10543409308835057.
2
The reassessment of trial perspectives from interim data--a critical view.基于中期数据对试验前景的重新评估——批判性观点。
Stat Med. 2006 Jan 15;25(1):23-36. doi: 10.1002/sim.2180.
3
Optimal conditional error functions for the control of conditional power.用于控制条件功效的最优条件误差函数。
Biometrics. 2004 Sep;60(3):715-23. doi: 10.1111/j.0006-341X.2004.00221.x.
4
Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.使用期中 Z 值或置信限控制 I 型和 II 型错误概率的无效性期中监测。
Clin Trials. 2009 Dec;6(6):565-73. doi: 10.1177/1740774509350327. Epub 2009 Nov 23.
5
Sample size re-estimation in group-sequential response-adaptive clinical trials.成组序贯反应自适应临床试验中的样本量重新估计
Stat Med. 2003 Dec 30;22(24):3843-57. doi: 10.1002/sim.1677.
6
Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.基于可检测治疗差异的临床试验序贯设计构建。
Stat Med. 2004 May 15;23(9):1413-24. doi: 10.1002/sim.1751.
7
Self-designing trial combined with classical group sequential monitoring.自我设计试验与经典序贯监测相结合。
J Biopharm Stat. 2005;15(4):667-75. doi: 10.1081/BIP-200062850.
8
[Analysis and importance of statistical power and sample size in empirical scientific research].[实证科学研究中统计功效与样本量的分析及重要性]
Wiad Lek. 2008;61(7-9):211-5.
9
A seamless phase II/III design with sample-size re-estimation.具有样本量重新估计的无缝II/III期设计。
J Biopharm Stat. 2009 Jul;19(4):595-609. doi: 10.1080/10543400902963193.
10
Adaptive statistical analysis following sample size modification based on interim review of effect size.基于效应量中期评估调整样本量后的适应性统计分析。
J Biopharm Stat. 2005;15(4):693-706. doi: 10.1081/BIP-200062855.